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A BS TR AC T
BACKGROUND
Results of trials and registry studies have shown lower long-term mortality after 
coronary-artery bypass grafting (CABG) than after percutaneous coronary interven-
tion (PCI) among patients with multivessel disease. These previous analyses did not 
evaluate PCI with second-generation drug-eluting stents.
METHODS
In an observational registry study, we compared the outcomes in patients with 
multivessel disease who underwent CABG with the outcomes in those who under-
went PCI with the use of everolimus-eluting stents. The primary outcome was all-
cause mortality. Secondary outcomes were the rates of myocardial infarction, 
stroke, and repeat revascularization. Propensity-score matching was used to as-
semble a cohort of patients with similar baseline characteristics.
RESULTS
Among 34,819 eligible patients, 9223 patients who underwent PCI with everolimus-
eluting stents and 9223 who underwent CABG had similar propensity scores and 
were included in the analyses. At a mean follow-up of 2.9 years, PCI with everolimus-
eluting stents, as compared with CABG, was associated with a similar risk of death 
(3.1% per year and 2.9% per year, respectively; hazard ratio, 1.04; 95% confidence 
interval [CI], 0.93 to 1.17; P = 0.50), higher risks of myocardial infarction (1.9% per 
year vs. 1.1% per year; hazard ratio, 1.51; 95% CI, 1.29 to 1.77; P<0.001) and repeat 
revascularization (7.2% per year vs. 3.1% per year; hazard ratio, 2.35; 95% CI, 2.14 
to 2.58; P<0.001), and a lower risk of stroke (0.7% per year vs. 1.0% per year; hazard 
ratio, 0.62; 95% CI, 0.50 to 0.76; P<0.001). The higher risk of myocardial infarction 
with PCI than with CABG was not significant among patients with complete revas-
cularization but was significant among those with incomplete revascularization 
(P = 0.02 for interaction).
CONCLUSIONS
In a contemporary clinical-practice registry study, the risk of death associated with 
PCI with everolimus-eluting stents was similar to that associated with CABG. PCI 
was associated with a higher risk of myocardial infarction (among patients with 
incomplete revascularization) and repeat revascularization but a lower risk of 
stroke. (Funded by Abbott Vascular.)
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Coronary-artery bypass grafting (CABG) and percutaneous coronary inter-vention (PCI) are treatment options for pa-
tients with multivessel coronary artery disease. 
Prior studies have shown a mortality benefit of 
CABG, as compared with PCI.1-4 However, these 
studies compared CABG with balloon angioplas-
ty, bare-metal stents, or first-generation drug-
eluting stents. Second-generation drug-eluting 
stents have thinner struts and have thinner and 
more biocompatible polymer with more uniform 
polymer coating of the strut surface, resulting in 
less inflammation and thrombogenicity, as com-
pared with the first-generation drug-eluting stents 
and even bare-metal stents.5
Consequently, the newer-generation drug-
eluting stents, especially the everolimus-eluting 
stent, have been shown to reduce the risks of 
death, myocardial infarction, and stent throm-
bosis, as compared with bare-metal stents or 
first-generation drug-eluting stents.6,7 However, 
previous studies did not compare CABG with 
PCI with the use of second-generation drug-
eluting stents. The recommendations of various 
national and international guidelines are based 
on studies of CABG versus PCI with the use of 
older-generation stents, but these guidelines have 
been applied routinely to contemporary practice.8
Our objective was to evaluate the outcomes 
with CABG, as compared with PCI with the use 
of everolimus-eluting stents, in patients who had 
multivessel coronary artery disease. We used a 
contemporary clinical-practice registry to iden-
tify participants.
Me thods
STUDY DESIGN AND OVERSIGHT
This study was a registry-based analysis involv-
ing patients with multivessel coronary artery dis-
ease who underwent isolated CABG surgery and 
patients who underwent PCI with everolimus-
eluting stents between January 1, 2008, and De-
cember 31, 2011, in New York. The study was 
designed by the first and last authors and was 
funded by Abbott Vascular. The registry data 
were collected by the data coordinators at par-
ticipating hospitals. The second and fifth au-
thors performed the analysis. The first author 
prepared the first draft of the manuscript, which 
was then reviewed and edited by the coauthors. 
The sponsor, who had no role in the design or 
conduct of the study, had the right to suggest 
changes to the manuscript, but final decisions 
regarding the content were made solely by the au-
thors. The first and last authors accept full respon-
sibility for the accuracy and completeness of the 
reported analyses and interpretations of the data.
REGISTRIES
The patients included in the study were identified 
from the Cardiac Surgery Reporting System 
(CSRS) and Percutaneous Coronary Intervention 
Reporting System (PCIRS) registries of the New 
York State Department of Health. No informed 
consent was required, because the data are ano-
nymized. To obtain follow-up information, the 
CSRS and PCIRS were linked with the New York 
State Vital Statistics Death registry with the use 
of patient identifiers and to the Statewide Plan-
ning and Research Cooperative System registry 
with the use of patient identifiers, unique hospi-
tal identifiers, and dates of admission, surgery, 
and discharge. Details regarding the registries are 
included in the Supplementary Appendix, avail-
able with the full text of this article at NEJM.org.
STUDY POPULATION
Patients were eligible for inclusion in the study if 
they had multivessel disease, which was defined 
as severe stenosis (≥70%) in at least two diseased 
major epicardial coronary arteries, and if they 
had undergone either PCI with implantation of 
an everolimus-eluting stent or CABG. Exclusion 
criteria were the following: revascularization with-
in 1 year before the index procedure; previous 
cardiac surgery (CABG or valve surgery), because 
such patients are less likely to undergo repeat 
CABG than to undergo PCI; severe left main cor-
onary artery disease (degree of stenosis, ≥50%); 
PCI with a stent other than an everolimus-eluting 
stent or with a combination of stents; myocardial 
infarction within 24 hours before the index pro-
cedure; and unstable hemodynamics or cardio-
genic shock.
OUTCOMES
The primary outcome of the study was all-cause 
mortality. Various secondary outcomes were also 
assessed, including the rates of myocardial infarc-
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tion, stroke, and repeat revascularization. Myo-
cardial infarction was defined as either proce-
dural, if it occurred as a complication after PCI or 
CABG (defined in both the CSRS and PCIRS reg-
istries as the presence of new Q waves), or spon-
taneous, if it was diagnosed at readmission (i.e., 
as an emergency admission with a principal di-
agnosis of myocardial infarction or a principal 
diagnosis of cardiogenic shock with a secondary 
diagnosis of myocardial infarction).
Stroke was categorized as occurring either 
within 30 days (in which case it was presumed 
to be a complication of the index procedure) or 
after 30 days (on the basis of readmission with 
a principal diagnosis of stroke). Repeat revascu-
larization was identified as any unstaged revas-
cularization after the index procedure; staged 
revascularization was defined as non–target-
vessel revascularization within 90 days after the 
index procedure. In addition, short-term events 
(those occurring in the hospital or ≤30 days af-
ter the procedure) were tabulated separately.
STATISTICAL ANALYSIS
Given the differences in the baseline characteris-
tics between eligible participants in the two 
groups (Table 1), propensity-score matching was 
used to identify a cohort of patients with similar 
baseline characteristics. The propensity score is a 
conditional probability of having a particular ex-
posure (PCI with everolimus-eluting stents ver-
sus CABG) given a set of baseline measured co-
variates.9,10 The propensity score was estimated 
with the use of a nonparsimonious multivariable 
logistic-regression model,11 with PCI with the 
use of everolimus-eluting stents as the dependent 
variable and all the baseline characteristics out-
lined in Table 1 as covariates. Matching was per-
formed with the use of a 1:1 matching protocol 
without replacement (greedy-matching algo-
rithm), with a caliper width equal to 0.2 of the 
standard deviation of the logit of the propensity 
score. Standardized differences were estimated 
for all the baseline covariates before and after 
matching to assess prematch imbalance and 
postmatch balance.12 Standardized differences 
of less than 10.0% for a given covariate indicate 
a relatively small imbalance.12
In the matched cohort, paired comparisons 
were performed with the use of McNemar’s test 
for binary variables and a paired Student’s t-test 
or paired-sample test for continuous variables. 
The comparative risks of primary and secondary 
outcomes were further adjusted for in the 
matched cohort with the use of a Cox propor-
tional-hazards regression model that was strati-
fied on the matched pair to preserve the benefit 
of matching.
Prespecified subgroup analyses were per-
formed on the basis of two types of characteris-
tics. Anatomical subgroups were based on three-
vessel disease versus two-vessel disease, with or 
without involvement of the territory of the 
proximal left anterior descending coronary ar-
tery, and on complete revascularization versus 
incomplete revascularization in the PCI cohort. 
Clinical subgroups were based on age (<80 years 
vs. ≥80 years), diabetes status (yes or no), and 
left ventricular ejection fraction (≥40% vs. 
<40%). In the subgroup analyses, to maintain 
the baseline balance between the PCI group and 
the CABG group, only the corresponding 
matched pairs in a subgroup were chosen. For 
example, in the subgroup of patients with diabe-
tes, only the matched pairs of patients with dia-
betes in the PCI group and in the CABG group 
were included in the analysis. Tests for interac-
tion were performed to assess for heterogeneity 
of treatment effect among subgroups.
Analyses of the primary and secondary out-
comes were also performed in a separate pro-
pensity-matched cohort of patients who under-
went CABG versus those who underwent PCI 
with first-generation drug-eluting stents (siroli-
mus-eluting or paclitaxel-eluting stents) and in a 
propensity-matched cohort of patients who un-
derwent PCI with everolimus-eluting stents ver-
sus those who underwent PCI with first-genera-
tion drug-eluting stents.
All reported P values are two-sided and have 
not been adjusted for multiple testing. All the 
analyses were performed with the use of SAS 
software, version 9.3 (SAS Institute).
R esult s
STUDY POPULATION
We identified 34,819 patients with multivessel 
disease who met our inclusion criteria (Fig. 1), of 
whom 16,876 (48.5%) underwent PCI with evero-
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Table 1. Baseline Characteristics before and after Propensity-Score Matching.*
Characteristic Before Matching After Matching
PCI  
(N = 16,876)
CABG  
(N = 17,943)
Standardized 
Difference
PCI  
(N = 9223)
CABG  
(N = 9223)
Standardized 
Difference
% %
Age
Mean (yr) 65.0±11.2 65.3±10.6 2.4 65.1±11.1 65.1±10.8 0.5
Distribution (%)
<59 yr 32.2 29.4 6.0 31.2 30.7 0.9
60–69 yr 31.8 33.9 4.4 32.8 33.1 0.6
70–79 yr 25.6 27.5 4.5 26.4 26.0 0.8
≥80 yr 10.4 9.1 4.4 9.6 10.1 1.6
Sex (%)
Male 70.8 74.2 7.7 72.6 72.9 0.7
Female 29.2 25.8 7.7 27.4 27.1 0.7
Body-surface area (m2) 2.03±0.27 2.04±0.27 <0.1 2.04±0.27 2.04±0.27 0.2
Hispanic ethnic group (%)† 12.4 8.9 11.4 11.0 11.0 0.0
Race (%)†
White 76.7 85.1 21.6 81.0 81.5 1.2
Black 11.2 7.7 12.1 9.3 9.1 0.7
Other 12.1 7.2 16.8 9.7 9.4 0.9
Diabetes (%) 39.0 40.6 3.1 39.0 39.5 1.2
Ejection fraction (%)
<20% 0.6 1.5 9.7 0.8 0.8 0.5
20–29% 2.9 6.5 16.8 4.1 4.4 1.4
30–39% 5.0 11.4 23.8 7.2 7.4 0.6
40–49% 12.2 19.0 18.7 15.7 15.4 1.0
≥50% 74.5 61.3 28.5 71.7 71.6 0.4
Data missing 4.8 0.3 29.1 0.5 0.5 0.5
Previous myocardial infarction (%)
1–7 Days before treatment 15.2 18.5 8.6 17.0 16.8 0.4
8–14 Days before treatment 1.2 5.2 23.0 2.0 2.0 0.5
15–20 Days before treatment 0.3 1.0 8.9 0.4 0.5 1.6
>20 Days before treatment 17.5 22.4 12.1 19.5 19.5 0.1
None 65.8 53.0 26.3 61.2 61.1 0.1
Cerebrovascular disease (%) 2.4 7.6 24.1 3.6 3.8 1.0
Peripheral arterial disease (%) 8.6 11.6 9.9 9.6 9.8 0.5
COPD (%) 5.3 12.5 25.4 7.6 7.7 0.4
Congestive heart failure (%)
None 93.9 85.2 28.8 91.3 91.2 0.4
At current admission 3.7 11.7 30.4 5.8 6.0 0.8
Before current admission 2.4 3.1 4.4 2.8 2.7 0.5
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limus-eluting stents and 17,943 (51.5%) under-
went CABG (Table 1). Before propensity-score 
matching, there were differences between the 
two groups in several of the baseline variables 
(Table 1). With the use of propensity-score 
matching, 9223 patients who underwent PCI 
with the use of everolimus-eluting stents were 
matched with 9223 patients who underwent 
CABG. The C-statistic for the model was 0.814. 
After matching, the standardized differences 
were less than 10.0% for all variables, indicating 
only small differences between the two groups 
(Table 1).
SHORT-TERM OUTCOMES
Short-term outcomes (in the hospital or ≤30 days 
after the index procedure) favored PCI with 
everolimus-eluting stents over CABG. PCI was 
associated with significantly lower risks of death 
(0.6% vs. 1.1%; hazard ratio, 0.49; 95% confi-
dence interval [CI], 0.35 to 0.69; P<0.001) and 
stroke (0.2% vs. 1.2%; hazard ratio, 0.18; 95% CI, 
0.11 to 0.29; P<0.001), but there was no signifi-
cant difference between the two groups in the 
risk of myocardial infarction (0.5% and 0.4%, 
respectively; hazard ratio, 1.37; 95% CI, 0.89 to 
2.12; P = 0.16).
PRIMARY OUTCOME
After a mean follow-up of 2.9 years, PCI with 
everolimus-eluting stents was associated with a 
risk of death that was similar to that associated 
with CABG (3.1% and 2.9% per year, respectively; 
hazard ratio, 1.04; 95% CI, 0.93 to 1.17; P = 0.50) 
Table 1. (Continued.)
Characteristic Before Matching After Matching
PCI  
(N = 16,876)
CABG  
(N = 17,943)
Standardized 
Difference
PCI  
(N = 9223)
CABG  
(N = 9223)
Standardized 
Difference
% %
Malignant ventricular arrhythmia (%) 0.4 0.8 6.3 0.5 0.6 0.9
Renal failure (%)
Requiring dialysis 2.5 2.8 2.3 2.4 2.7 1.5
Creatinine level in patients not  
requiring dialysis‡
<1.3 mg/dl 78.2 73.6 10.9 77.1 76.4 1.8
1.3–1.5 mg/dl 12.2 13.4 3.8 12.6 13.0 1.1
1.6–2.0 mg/dl 5.0 6.7 6.9 5.4 5.5 0.3
>2.0 mg/dl 2.1 3.5 8.4 2.4 2.5 0.5
No. of diseased vessels (%)
2
With proximal LAD artery 18.8 17.8 2.7 26.3 25.9 0.8
Without proximal LAD artery 55.1 15.7 90.5 29.5 29.2 0.5
3
With proximal LAD artery 8.6 35.5 68.7 15.3 15.2 0.4
Without proximal LAD artery 17.5 31.0 32.0 28.9 29.6 1.6
Prior PCI (%) 31.7 18.0 32.0 24.5 24.1 1.0
* Plus–minus values are means ±SD. The standardized differences are reported as percentages; a difference of less than 10.0% indicates a 
relatively small imbalance. CABG denotes coronary-artery bypass grafting, COPD chronic obstructive pulmonary disease, LAD left anterior 
descending, and PCI percutaneous coronary intervention.
† Race and ethnic group were self-reported.
‡ To convert the values for creatinine to micromoles per liter, multiply by 88.4.
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(Table 2 and Fig. 2A). The results were largely 
similar in the subgroup analyses that were based 
on vessel anatomy (Table S1 in the Supplemen-
tary Appendix) and clinical characteristics (Table 
S2 in the Supplementary Appendix), including in 
the subgroup analysis that was based on diabetes 
status (P = 0.45 for interaction).
MYOCARDIAL INFARCTION
PCI with everolimus-eluting stents was associat-
ed with a higher risk of a first myocardial infarc-
tion than was CABG (1.9% vs. 1.1% per year; 
hazard ratio, 1.51; 95% CI, 1.29 to 1.77; P<0.001) 
(Table 2 and Fig. 2B). This higher risk of myocar-
dial infarction after PCI was driven by a higher 
risk of spontaneous myocardial infarction (haz-
ard ratio, 1.55; 95% CI, 1.31 to 1.82; P<0.001), 
with no significant difference between the two 
study groups in the risk of procedural myocar-
dial infarction (hazard ratio, 1.36; 95% CI, 0.68 
to 2.71; P = 0.39). The higher risk of myocardial 
infarction after PCI with everolimus-eluting 
stents, as compared with CABG, was not signifi-
cant in matched pairs in which the patient in the 
PCI group had complete revascularization but 
was significant in pairs in which the patient in 
the PCI group had incomplete revascularization 
(P = 0.02 for interaction) (Table S1 in the Supple-
mentary Appendix). The results were generally 
similar in other subgroups (Tables S1 and S2 in 
the Supplementary Appendix) with a higher risk 
of myocardial infarction with PCI than with 
CABG, although there was a nonsignificant trend 
toward a less pronounced difference among pa-
tients with two-vessel disease than among those 
with three-vessel disease (P = 0.14 for interaction) 
(Table S1 in the Supplementary Appendix).
STROKE
PCI with everolimus-eluting stents was associat-
ed with a lower risk of a first stroke than was 
CABG (0.7% vs. 1.0% per year; hazard ratio, 0.62; 
95% CI, 0.50 to 0.76; P<0.001) (Table 2 and Fig. 
2C). The difference was driven largely by a lower 
short-term (≤30 days) risk of stroke with PCI with 
everolimus-eluting stents, as compared with 
CABG (hazard ratio, 0.18; 95% CI, 0.11 to 0.29; 
P<0.001), with no significant difference in a 
landmark analysis that examined only events af-
ter 30 days (hazard ratio, 1.05; 95% CI, 0.81 to 
1.37; P = 0.69). The results were generally similar 
in subgroup analyses (Tables S1 and S2 in the 
Supplementary Appendix).
REPEAT REVASCULARIZATION
PCI with everolimus-eluting stents was associat-
ed with a higher risk of a first repeat-revascular-
ization procedure than was CABG (7.2% vs. 3.1% 
per year; hazard ratio, 2.35; 95% CI, 2.14 to 2.58; 
P<0.001) (Table 2 and Fig. 2D). This difference 
34,819 Were included in study analysis
16,876 Underwent isolated CABG
17,943 Underwent PCI with everolimus-
eluting stent
116,915 Patients in New York underwent  
CABG or PCI for multivessel coronary
artery disease for the first time
in 2008–2011
 82,096 Were excluded
4,612 Were not residents of
New York
4,351 Had invalid personal
identifier
12,183 Had left main coronary
artery disease
1,898 Had previous revascular-
ization ≤1 yr before 
the index procedure
15,589 Underwent previous
open-heart surgery
491 Had plan for a follow-up
CABG as part of a staged
treatment strategy for
the index PCI
428 Had emergency PCI or
CABG because of com-
plication during diagnos-
tic catheterization
12,984 Had acute myocardial
infarction <24 hr
previously
386 Had shock
640 Had unstable hemo-
dynamics
47 Had stent thrombosis
2,484 Underwent index PCI
with everolimus-eluting
stent and at least 
one other type of stent
26,003 Underwent index PCI
with stent other than
everolimus-eluting stent
18,446 Were included in propensity-score–
matched analysis
9223 Underwent isolated CABG
9223 Underwent PCI with everolimus-
eluting stent
Figure 1. Study Population.
CABG denotes coronary-artery bypass graft surgery, 
and PCI percutaneous coronary intervention.
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was less pronounced among patients with two-
vessel disease than among those with three-ves-
sel disease (P = 0.02 for interaction), although 
CABG was favored in both (Table S1 in the Sup-
plementary Appendix). Similarly, the difference 
between PCI and CABG was less pronounced in 
the subgroup of patients who had complete re-
vascularization than it was in the subgroup of 
those who had incomplete revascularization 
(P<0.001 for interaction), again with CABG fa-
vored in both (Table S1 in the Supplementary Ap-
pendix). The results were largely similar (in favor 
of CABG) in the other subgroups (Tables S1 and 
S2 in the Supplementary Appendix). Among all 
repeat revascularizations in the two study groups, 
most repeat revascularizations were performed 
by means of PCI (92.6%), with only a minority 
being performed by means of CABG (7.4%).
SENSITIVITY ANALYSIS
In an analysis of CABG versus PCI with first-gen-
eration drug-eluting stents (6128 matched pairs), 
CABG was associated with nonsignificantly low-
er rates of death (2.7% and 3.0% per year, respec-
tively; P = 0.21) and with significantly lower risks 
of myocardial infarction (P<0.001) and revascu-
larization (P<0.001) but with a trend toward a 
higher risk of stroke (P = 0.05) (Table S3 in the 
Supplementary Appendix). In an analysis of PCI 
with everolimus-eluting stents versus PCI with 
first-generation drug-eluting stents (8801 
matched pairs), everolimus-eluting stents were 
associated with lower risks of myocardial infarc-
tion (P<0.001) and revascularization (P = 0.03) 
but similar risks of other outcomes (Table S4 in 
the Supplementary Appendix).
Discussion
In a contemporary cohort of patients with multi-
vessel coronary artery disease, the risk of death 
associated with PCI with everolimus-eluting 
stents was similar to that associated with CABG. 
PCI was associated with a higher risk of myocar-
dial infarction (mainly among patients who had 
incomplete revascularization) and repeat revas-
cularization, whereas CABG was associated with 
an increased risk of stroke. Short-term results 
favored PCI, with lower risks of death and stroke.
Randomized trials comparing PCI with CABG 
have not been typically powered to evaluate dif-
ferences in the rates of myocardial infarction, 
stroke, and death from any cause; instead, they 
have been based on composite outcomes that 
include repeat revascularization. To create data 
sets of sufficient size to analyze these less fre-
quent outcomes, one option is to perform meta-
analyses of clinical-trial data. For example, one 
recent meta-analysis included six trials (involv-
ing 6055 patients) comparing PCI with the use 
of either first-generation drug-eluting stents or 
bare-metal stents with CABG.13 Rates of death, 
myocardial infarction, and repeat revasculariza-
tion were significantly lower with CABG than 
with PCI, with a trend toward a higher rate of 
stroke with CABG.
Another approach is to use clinical-practice 
registries or other observational data sets. For 
example, in one analysis that included nearly 
190,000 patients from the American College of 
Cardiology Foundation PCI Registry and the 
Society of Thoracic Surgeons Adult Cardiac 
Surgery Database, in which adjustment was 
made for propensity scores and inverse probabil-
ity weighting, mortality at 4 years was lower 
among patients who had undergone CABG than 
among those who had undergone PCI (78% of 
whom had received first-generation drug-eluting 
stents).14
Table 2. Risk of Primary and Secondary Outcomes in the Propensity-Score–
Matched Cohort.*
Outcome
No. of Patients 
with Event
Event  
Rate
Hazard Ratio
(95% CI) P Value
%/yr
Death
PCI 768 3.10 1.04 (0.93–1.17) 0.50
CABG 815 2.86 Reference
Myocardial infarction
PCI 462 1.87 1.51 (1.29–1.77) <0.001
CABG 322 1.13 Reference
Stroke
PCI 178 0.72 0.62 (0.50–0.76) <0.001
CABG 277 0.97 Reference
Revascularization
PCI 1793 7.25 2.35 (2.14–2.58) <0.001
CABG 883 3.10 Reference
* The propensity-score–matched cohort included 9223 patients in the PCI group 
and 9223 patients in the CABG group.
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The relevance of these previous studies to 
current-day PCI with second-generation drug-
eluting stents is debatable. Restenosis and stent 
thrombosis are two potentially serious compli-
cations of PCI, which are associated with signifi-
cant increases in the rates of myocardial infarc-
tion and death.15,16 A wealth of data from studies 
of second-generation drug-eluting stents, espe-
cially everolimus-eluting stents, have shown re-
ductions in the risks of death, myocardial in-
farction, and stent thrombosis when such stents 
are compared with bare-metal stents or first-
generation drug-eluting stents.6,7,17,18 Data from 
the New York State registries show a gradual 
bridging of the gap between CABG and PCI with 
respect to mortality, from the balloon-angioplasty 
era (40 to 50% reduction in mortality with CABG 
among patients with three-vessel disease),2 to the 
bare-metal–stent era (24 to 36% reduction),3 to 
the era of first-generation drug-eluting stents 
(20 to 29% reduction),4 to the use of second-
generation drug-eluting stents (no significant 
reduction in the present study). Data from the 
New York State registries also show decreases in 
the rate of repeat revascularization with PCI, 
from the balloon-angioplasty era (37.0% of pa-
tients),2 to the bare-metal–stent era (35.1%),3 to 
the era of first-generation drug-eluting stents 
(30.6%),4 to the use of second-generation drug-
eluting stents (19.4% in the present study).
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Figure 2. Cumulative Risks of the Study Outcomes in the Matched Cohort.
In each panel, the inset shows the same data on an enlarged y axis.
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In the current study, PCI with the use of 
everolimus-eluting stents was associated with a 
higher risk of myocardial infarction than CABG. 
However, this difference in risk was not signifi-
cant in the subgroup of matched pairs in which 
the patients who underwent PCI had complete 
revascularization. Incomplete revascularization 
has been shown to be associated with a signifi-
cant increase in the risks of death and myocardial 
infarction.19,20 Thus, the choice between CABG 
and PCI with everolimus-eluting stents may de-
pend on whether complete revascularization can 
be achieved with PCI. If the answer is yes, the 
choice between PCI and CABG should be made 
on the basis of weighing the short-term risk of 
death and stroke with CABG against the long-
term risk of repeat revascularization with PCI. If 
complete revascularization does not appear to be 
feasible on the basis of anatomy, our data then 
suggest that such patients do better with CABG.
Some limitations of our analysis should be 
considered. This was a nonrandomized, obser-
vational study and hence suffers from potential 
selection and ascertainment bias despite robust 
propensity-score matching. The registries did not 
capture variables such as hypertension, hyper-
lipidemia, and smoking status, factors that affect 
long-term outcomes; therefore these variables 
could not be included in the propensity scores. 
The database does not distinguish between the 
cobalt–chromium and platinum–chromium evero-
limus-eluting stents. In addition, analyses strati-
fied according to Synergy between PCI with Taxus 
and Cardiac Surgery (SYNTAX; www.syntaxscore 
.com) score could not be performed, owing to 
insufficient data to calculate the score. We did 
not have data on stent thrombosis. However, 
most stent thrombosis results in death or myo-
cardial infarction, which are outcomes that were 
captured in the present study. In addition, the 
study did not include other neurologic out-
comes, such as cognitive decline or transient 
ischemic attacks. The definition of procedural 
myocardial infarction did not capture events 
determined by biomarker elevations, because the 
routine collection of biomarkers after the proce-
dure is not mandated in New York.
In conclusion, in this contemporary cohort of 
patients with multivessel coronary artery disease, 
PCI with everolimus-eluting stents, as compared 
with CABG, was associated with lower short-
term risks of death and stroke and with a similar 
long-term risk of death. PCI was also associated 
with a higher risk of myocardial infarction (among 
patients who had incomplete revascularization) 
and repeat revascularization, whereas CABG was 
associated with a higher risk of stroke.
Supported by Abbott Vascular.
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